Prior research has demonstrated that CD8A is associated with the presence of CD8+ T cells which can exert anti‐tumour effects, indicating better immunotherapy outcomes, whereas PD‐L1 is an immune checkpoint protein linked to tumour cells evading immune responses, potentially leading to poor patient prognosis. This evidence concerns the gene CD8A and neoplasm.